Journal Der Deutschen Dermatologischen Gesellschaft最新文献

Contact allergy to an electronic device. 接触性电子设备过敏。

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-05-13 DOI: 10.1111/ddg.15775

Margitta Worm, Julia Oberschmied, Elsbeth Oestmann

引用次数: 0

Cutaneous manifestations of dermatomyositis in individuals with dark skin: A review of reported cases. 皮肤黝黑者皮肌炎的皮肤表现：报告病例的回顾。

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-05-13 DOI: 10.1111/ddg.15717

Edgar Akuffo-Addo, Samia Rahman, Kaitlyn Ramsay, Vincent Piguet, Marissa Joseph

引用次数: 0

Incidence trends of primary cutaneous B- and T-cell lymphoma before and after the COVID-19 pandemic. 新冠肺炎大流行前后原发性皮肤B细胞淋巴瘤和t细胞淋巴瘤的发病率趋势

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-05-09 DOI: 10.1111/ddg.15730

Ioannis-Alexios Koumprentziotis, Aikaterini Niforou, Stella Kaliampou, Antonios Tsimpidakis, Maria Gerochristou, Leonidas Marinos, Alexander Stratigos, Evangelia Papadavid, Vasiliki Nikolaou

引用次数: 0

Abatacept-induced lupus erythematosus tumidus: A case report and literature review. 阿巴那肽致红斑狼疮1例并文献复习。

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-05-08 DOI: 10.1111/ddg.15720

María Olivares-Guerrero, Ana Jiménez-Sánchez, Sonsoles Berenguer-Ruiz, Mario Aparicio-Domínguez, Mar Llamas-Velasco

引用次数: 0

German-Austrian guideline on screening for anal dysplasia and anal carcinoma in people living with HIV. 德国-奥地利艾滋病毒感染者肛门发育不良和肛门癌筛查指南。

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-05-05 DOI: 10.1111/ddg.15719

David Chromy, Felix Aigner, Jürgen C Becker, Markus Bickel, Andrea Brunner, Johannes Classen, Monika Hampl, Doris Helbig, Marcus Hentrich, Franc Hetzer, Christian Hoffmann, Johannes Jongen, Elmar Joura, Reinhard Kirnbauer, Alexander Kreuter, Gerold Felician Lang, Memo Mokhles, Frank Oellig, Mark Oette, Anja Potthoff, Andreas D Rink, Andreas Salat, Axel Jeremias Schmidt, Robert Siegel, Georg Stary, Ricardo Niklas Werner, Gerhard Weyandt, Ulrike Wieland, Stefan Essern

{"title":"German-Austrian guideline on screening for anal dysplasia and anal carcinoma in people living with HIV.","authors":"David Chromy, Felix Aigner, Jürgen C Becker, Markus Bickel, Andrea Brunner, Johannes Classen, Monika Hampl, Doris Helbig, Marcus Hentrich, Franc Hetzer, Christian Hoffmann, Johannes Jongen, Elmar Joura, Reinhard Kirnbauer, Alexander Kreuter, Gerold Felician Lang, Memo Mokhles, Frank Oellig, Mark Oette, Anja Potthoff, Andreas D Rink, Andreas Salat, Axel Jeremias Schmidt, Robert Siegel, Georg Stary, Ricardo Niklas Werner, Gerhard Weyandt, Ulrike Wieland, Stefan Essern","doi":"10.1111/ddg.15719","DOIUrl":"https://doi.org/10.1111/ddg.15719","url":null,"abstract":"People with HIV are up to 100 times more likely to develop anal carcinoma compared to the general population. Diagnosing and treating precursor lesions, specifically high-grade anal dysplasia, can significantly reduce the risk of developing anal carcinoma. This S2k-guideline outlines the factors that increase the likelihood of developing anal carcinoma and its precursors, including advancing age, a low CD4+ T-lymphocyte nadir, active cigarette smoking, receptive anal intercourse, or persistent infection with high-risk (HR) types of human papillomavirus (HPV). Screening is primarily recommended for all men who have sex with men (MSM) and transgender women with HIV starting at age 35, and all people with HIV starting at age 45. After inspection and digital anorectal examination, anal cytology is collected. An HR-HPV test may be performed. If clinical abnormalities are present or if cytology shows \"ASC-US or worse\", a referral for high-resolution anoscopy (HRA) is indicated. If lesions are found during HRA, a biopsy should be obtained. Anal intraepithelial neoplasia (AIN) grade-III or AIN-II p16-positive correspond to high-grade dysplasia and require treatment. The most strongly recommended therapeutic options are electrocautery, 85% trichloroacetic acid, and surgical excision. Finally, the guideline discusses how these screening recommendations can be applied to individuals without HIV.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interleukin-13 inhibition and cancer risk: A Mendelian randomization study. 白介素-13抑制与癌症风险：孟德尔随机研究。

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-05-03 DOI: 10.1111/ddg.15718

Zhenwei Tang, Yu Chen

引用次数: 0

Calcinosis cutis of the lower legs - hyperphosphatemic familial tumoral calcinosis in a patient with GALNT3 mutation. 下肢皮肤钙质沉着症- GALNT3突变患者的高磷血症家族性肿瘤钙质沉着症。

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-05-02 DOI: 10.1111/ddg.15716

David Ranzinger, Tobias Schaefer, Franziska Schauer, Kilian Eyerich, Anna Caroline Pilz

引用次数: 0

Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab. 停药后特应性皮炎复发和复发的预测因素：JAK1抑制剂与dupilumab。

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-05-02 DOI: 10.1111/ddg.15688

Hanwen Wu, Jiling Zhu, Nali Yang, Xiaolin Ji, Zhenyan Li, Yiwen Zhou, Qiuyang Xu, Yahui Ye, Zicheng Bai, Jingying Wang, Zhiming Li

{"title":"Atopic dermatitis relapse after treatment discontinuation and predictive factors for relapse: JAK1 inhibitors versus dupilumab.","authors":"Hanwen Wu, Jiling Zhu, Nali Yang, Xiaolin Ji, Zhenyan Li, Yiwen Zhou, Qiuyang Xu, Yahui Ye, Zicheng Bai, Jingying Wang, Zhiming Li","doi":"10.1111/ddg.15688","DOIUrl":"https://doi.org/10.1111/ddg.15688","url":null,"abstract":"Background and objectives: In the clinical management of atopic dermatitis (AD), treatment discontinuations and subsequent disease relapse are common. Understanding relapse patterns following treatment discontinuation in AD patients is therefore essential. This study aims to investigate the time to relapse and identify predictive factors in patients with moderate-to-severe AD who responded to treatment with selective Janus kinase 1 (JAK1) inhibitors (upadacitinib or abrocitinib) or dupilumab.Patients and methods: This single-center, retrospective cohort analysis reviewed the data for patients aged ≥ 12 years with moderate-to-severe AD who responded to either JAK1 inhibitors or dupilumab within 16 weeks. The primary outcome measures included the median time to skin lesion relapse after treatment discontinuation. Additionally, predictors for relapse were explored.Results: Within 72 weeks after discontinuation, the median time to skin lesion relapse after discontinuation for JAK1 inhibitor and dupilumab responders was 60 and 457 days, respectively. Overall, 52.9% and 34.6% of patients who used JAK1 inhibitors and dupilumab reported AD skin lesion relapse (average hazard ratio = 2.58, 95% confidence interval: 1.25-5.33, p = 0.01). No other factors influencing AD relapse were identified.Conclusions: After treatment discontinuation, Dupilumab showed relatively longer efficacy than JAK1 inhibitors, resulting in a lower risk of relapse.","PeriodicalId":14758,"journal":{"name":"Journal Der Deutschen Dermatologischen Gesellschaft","volume":" ","pages":""},"PeriodicalIF":5.5,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144013891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Granuloma annulare following SARS-CoV-2 infection: a new case and review of the literature. SARS-CoV-2感染后的环状肉芽肿一例及文献复习

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-05-02 DOI: 10.1111/ddg.15746

Biagio Scotti, Miriam Leuzzi, Bianca Maria Piraccini, Michelangelo La Placa

引用次数: 0

Sclerotic skin in Hutchinson-Gilford progeria syndrome: Reversible senescent phenotype. 哈钦森-吉尔福德早衰综合征的皮肤硬化：可逆的衰老表型。

IF 5.5 4区医学

Journal Der Deutschen Dermatologischen Gesellschaft Pub Date : 2025-04-30 DOI: 10.1111/ddg.15709

Donghee Kwak, Jun-Oh Shin, Kihyuk Shin, Byungsoo Kim, Moon-Bum Kim, Yun Hak Kim, Hyun-Chang Ko

引用次数: 0